September 20, 2024 – BD introduced the industrial launch of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe and the most recent capability enlargement of the BD Neopak™ Glass Prefillable Syringe platform to serve the rising marketplace for biologic therapies.

The BD Neopak™ Glass Prefillable Syringe platform is designed to deal with key improvement wants for biologics. Our clients have obtained approval to make use of this platform in additional than 24 indications together with Crohn’s illness, atopic dermatitis, heart problems and several other uncommon ailments.

BD has expanded the utility of this platform with the industrial launch of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe. This resolution options an 8-millimeter needle size and a thinner-walled cannula to optimize subcutaneous supply of upper viscosity drug profiles by decreasing the injection power and time required to realize strong resolution viscosity. This development allows pharmaceutical builders to interrupt via design limitations and enhance move and value past present limitations in comparison with an ordinary half-inch needle.

Extra data